Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
7.85    -0.15 (-1.88%)
Bid:
7.70
Ask:
8.00
Spread: 0.30 (3.896%)
Market Cap: £51.44m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Kromek Contract Wins

11 Dec 2014 07:00

RNS Number : 4521Z
Kromek Group PLC
11 December 2014
 



11 December 2014

 

Kromek Group plc

("Kromek" or the "Company")

 

Nuclear detection market contract extension with leading global security company

 

Progress achieved across medical, nuclear and security markets as Kromek expands customer base with new contract wins

 

Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce that it has been awarded a $1.0m contract extension by a leading global security company providing innovative systems, products and solutions to government and commercial customers worldwide. This follows the successful completion of the first phase for the design of Cadmium Zinc Telluride ("CZT") based detectors and ASIC for nuclear safeguard markets.

 

Under the terms of the contract for this second phase, Kromek will focus on the delivery of the new ASIC and detectors as well as the testing and characterization of detector modules. The Company expects to deliver this over the next 12 months.

 

Additionally, the Company has been awarded several new contracts, worth approximately £0.7m in aggregate with £0.4m realisable in the current financial year, for applications across the Company's three segments.

 

The majority of the sales are in the medical industry, with approximately $0.4m attributable to bone mineral densitometry ("BMD") applications. This includes a contract from a leading global healthcare and diagnostics company for the first phase of a project to incorporate the Company's detector modules into their diagnostics systems. In addition, Kromek has received further contracts from two of its existing OEM customers for CZT-based detector modules for BMD applications.

 

Innovate UK (previously the Technology Strategy Board), sponsored by the UK Government's Department for Business, Innovation & Skills, has awarded Kromek a contract, worth approximately £0.2m, for an 18-month programme for the development of a novel radiation detector for the medical and nuclear markets. This follows the successful delivery of previous projects, and is the fourth contract to be awarded to Kromek by Innovate UK in the current financial year.

 

Kromek has expanded its customer base with the award of its first contract from another global security technology group. Additionally, the Company won a new contract worth approximately $0.25m for the supply of OEM components for its baggage screening product for aviation security.

 

Arnab Basu, CEO of Kromek, said: "We are delighted to have been awarded these contracts, which reflect progress across all of our business divisions and in multiple geographies. That this includes both new and existing customers provides further validation of our technological strength to manipulate a material such as CZT to enable our customers to make commercially viable products. We look forward to working with our partners to continue to develop leading-edge radiation detection solutions to enable safer travel, safer environments and better patient outcomes."

 

 

Enquiries

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

01740 626 060

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley - Corporate Finance

Charles Leigh-Pemberton - Broking

0207 886 2500

Luther Pendragon

Harry Chathli, Claire Norbury, Alexis Gore, Ivana Petkova

0207 618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 250 pieces of IP.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

 

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over a hundred full time employees across its global operations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTGDBDDBGBBGSB
Date   Source Headline
4th Jun 20267:00 amRNSGrant of Long-Term Incentives
2nd Jun 20267:00 amRNS-RLaunch of new interactive investor hub
1st Jun 20267:00 amRNSPDMR/Director Shareholding, Issue of Equity & TVR
12th May 20267:00 amRNSFull Year 2026 Trading Update
30th Apr 20262:30 pmRNSIssue of Equity, TVR & Extension of Options
9th Mar 20261:36 pmRNSDirector Share Purchase
9th Mar 20261:36 pmRNSDirector Share Purchase
20th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSNotice of Results
15th Dec 202512:27 pmRNSHolding(s) in Company
3rd Nov 202511:32 amRNSDirector Share Purchase
28th Oct 20257:00 amRNSGrant of Options, PDMR Dealings and TVR
27th Oct 20252:16 pmRNSResult of AGM
27th Oct 20257:00 amRNSPre-close Trading Statement
3rd Oct 202510:06 amRNSNotice of AGM and Publication of Annual Report
16th Sep 20257:00 amRNSFinal Results
11th Aug 20257:00 amRNSNew Biosecurity Award from UK MoD
28th Jul 20257:00 amRNS$5m received under Siemens Healthineers agreement
21st Jul 20257:00 amRNS£1.7m contract win under UK Government Framework
23rd Jun 202511:40 amRNS-RCapital Markets Day Presentation
18th Jun 20257:00 amRNSCapital Markets Day
16th Jun 20254:02 pmRNSHolding(s) in Company
9th Jun 20257:00 amRNSIssue of Equity and Total Voting Rights
3rd Jun 20251:53 pmRNSHolding(s) in Company
3rd Jun 20257:00 amRNSCapital Markets Day
28th May 20257:00 amRNSNew Nuclear Security Orders
8th May 20257:05 amRNSDirectorate Change
8th May 20257:00 amRNSFull Year 2025 Trading Update
17th Feb 20257:00 amRNS$25m received under Siemens Healthineers agreement
7th Feb 20251:49 pmRNSHolding(s) in Company
6th Feb 202512:35 pmRNSHolding(s) in Company
30th Jan 20257:01 amRNSInterim Results
30th Jan 20257:00 amRNSKromek Signs Agreements with Siemens Healthineers
13th Dec 202412:20 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM and Publication of Annual Report
28th Oct 20247:01 amRNSFinal Results and Publication of Annual Report
28th Oct 20247:00 amRNSFinancing Update
30th Sep 20247:00 amRNSUpdate on Full Year Results
23rd Sep 20247:00 amRNSKromek selected for UK Government Framework
16th Sep 20247:00 amRNSKromek awarded £2.0m contract from UK MOD
21st Aug 202410:14 amRNSHolding(s) in Company
7th Jun 20249:20 amRNSCancellation of outstanding Convertible Loan Notes
29th May 20247:00 amRNSFY 2024 Trading Update
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.